Results 201 to 210 of about 443,792 (339)

Ursolic Acid Alleviates Orchitis via Modulating Ferroptosis in Peritubular Myoid Cells of Testis

Animal Research and One Health, EarlyView.
Ursolic acid modulates key ferroptosis‐related pathways in the peritubular myoid cells of the testis in forest musk deer. ABSTRACT Chronic stress adversely affects reproductive health, increasing susceptibility to pathologies such as orchitis. Additionally, the maintenance of iron homeostasis is essential for preserving the function of the testicles ...
Yang Wang, Tianqi Jin, Zexin Chen, Ye Gong, Qimin Liu, Zifang Wu, Heran Cao, Yan Li, Yuyan Liu, Tianhao Yang, Zhihong Jiang, Wuzi Dong   +11 more
wiley   +1 more source

Tobacco 'antisense' lines with a stepwise reduction in Rubisco allowed a network approach to the regulation of photosynthesis, metabolism, allocation and growth. [PDF]

Planta
Stitt M.
europepmc   +1 more source

TWEAK/Fn14 signaling drives oxidative cardiac injury in systemic lupus erythematosus: Evidence from patient biomarker studies, lupus mouse models, and cardiomyocyte assays

Arthritis &Rheumatology, Accepted Article.
Objective Cardiac involvement is a major cause of morbidity in systemic lupus erythematosus (SLE). Tumor necrosis factor–like weak inducer of apoptosis (TWEAK) is elevated in SLE, but its contribution to lupus‐associated cardiac injury is unclear. We investigated the role of TWEAK/Fn14 signaling in SLE‐related cardiomyopathy and its potential as a ...
Yale Liu, Zhu Yan, Xueting Peng, Meixuan Li, Juan Wang, Yan Zhang, Xiaoqian Hu, Mingzhu Zhou, Kaixuan Ren, Dan Zhang, Xingyi Guo, Yumin Xia, Huanhuan Huo   +12 more
wiley   +1 more source

HIV Vpr induces demethylation of the SNCA antisense promoter, leading to neurocognitive impairment. [PDF]

Sci Rep
Santerre M, Wang Y, Kalamarides D, Park J, Kirby LG, Chin J, Jelinek J, Shcherbik N, Sawaya BE.   +8 more
europepmc   +1 more source

Switching disease‐modifying therapies in patients with spinal muscular atrophy: A systematic review on effectiveness outcomes

British Journal of Clinical Pharmacology, EarlyView.
With multiple disease‐modifying therapies now available, treatment switching has become an important clinical consideration in the management of spinal muscular atrophy (SMA). While some switches are prompted by suboptimal clinical response, more commonly they are driven by treatment burden, convenience, or adverse events.
Andrej Belančić, Elvira Meni Maria Gkrinia, Patrick Eustaquio, Andrea Katrin Faour, Dinko Vitezić   +4 more
wiley   +1 more source

Antisense transcription can induce expression memory via stable promoter repression. [PDF]

Genome Biol
Mutzel V, Schwämmle T, Oeverdieck S, Librenjak L, Boesen B, Bothe M, Gjaltema RAF, Dunkel I, Noviello G, Schulz EG.   +9 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

Genomic Aberrations of Antisense Gene Transcripts in Head and Neck Cancer. [PDF]

Cells
Ye J, Abbang SM, Ng YK, Lui VWY.
europepmc   +1 more source

RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention.

Neuron, 2013
Christopher J. Donnelly, Ping-Wu Zhang, Jacqueline T. Pham, A. Haeusler, Nipun A. Mistry, Svetlana Vidensky, E. Daley, E. M. Poth, Benjamin Hoover, Daniel M. Fines, N. Maragakis, P. Tienari, L. Petrucelli, Bryan J. Traynor, Bryan J. Traynor, Jiou Wang, F. Rigo, C. Bennett, S. Blackshaw, R. Sattler, J. Rothstein   +20 more
semanticscholar   +1 more source

The evolving therapeutic landscape of spinal muscular atrophy – A scoping review of investigational agents, emerging delivery technologies and strategic innovations

British Journal of Clinical Pharmacology, EarlyView.
Spinal muscular atrophy (SMA) is a severe neuromuscular disease with emerging therapeutic complexity. This review aims to systematically map the global pipeline of investigational treatments for SMA. Using ClinicalTrials.gov and complementary international registries, we identified 21 planned or ongoing interventional trials from 2020 to 2025 targeting
Andrej Belančić, Patrick Eustaquio, Elvira Meni Maria Gkrinia, Ivana Stević, Eugen Javor, Yun Wah Lam, Slobodan Janković, Dinko Vitezić   +7 more
wiley   +1 more source